3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Melanoma
7
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Recurrence
4
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Lung Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Mycosis Fungoides
1
Multiple Myeloma
1
Interventions
cemiplimab
1
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Cutaneous Squamous Cell Carcinoma
×
cemiplimab
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts